News | October 28, 2021
Indian Pharma Market witnesses rise in volumes and prices in September.
Acute therapies continue to report strong growth compared to chronic ones.
Acute therapies continue to report strong growth compared to chronic ones.
Cipla has reported consolidated financial results for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
